Biophysical study of bevacizumab structure and bioactivity under thermal and pH-stresses

European Journal of Pharmaceutical Sciences

Volumn 105, Issue , 2017, Pages 127-136

  Sousa, Flávia ^a,b,c,d   Sarmento, Bruno ^a,b,c   Neves Petersen, Maria Teresa ^e  

^a UNIVERSITY OF PORTO   (Portugal)

^b INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^e AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bevacizumab; Circular dichroism; Denaturation; Melting temperature; Monoclonal antibody; Secondary structure; Spectroscopy; Tertiary structure

Indexed keywords

BEVACIZUMAB;

ARTICLE; BIOLOGICAL ACTIVITY; BIOPHYSICS; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; COOLING; DENATURATION; DRUG STRUCTURE; FLUORESCENCE SPECTROSCOPY; HEATING; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MELTING POINT; PH; PRIORITY JOURNAL; ROOM TEMPERATURE; TEMPERATURE STRESS; THERMOSTABILITY; UMBILICAL VEIN ENDOTHELIAL CELL; CELL CULTURE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HEAT; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SPECTROFLUOROMETRY;

BEVACIZUMAB; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CIRCULAR DICHROISM; HOT TEMPERATURE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SPECTROMETRY, FLUORESCENCE;

EID: 85019191450     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2017.05.019     Document Type: Article

References (35)

1. Abbas, S.A., Gaspar, G., Sharma, V.K., Patapoff, T.W., Kalonia, D.S., Application of second-derivative fluorescence spectroscopy to monitor subtle changes in a monoclonal antibody structure. J. Pharm. Sci. 102 (2013), 52–61.
2. Abrishami, M., Zarei-Ghanavati, S., Soroush, D., Rouhbakhsh, M., Jaafari, M.R., Malaekeh-Nikouei, B., Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration. Retina 29 (2009), 699–703.
3. Baldwin, R.L., Zimm, B.H., Are denatured proteins ever random coils?. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 12391–12392.
4. Beck, A., Wagner-Rousset, E., Ayoub, D., Van Dorsselaer, A., Sanglier-Cianférani, S., Characterization of therapeutic antibodies and related products. Anal. Chem. 85 (2013), 715–736.
5. Berkowitz, S.A., Engen, J.R., Mazzeo, J.R., Jones, G.B., Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars. Nat. Rev. Drug Discov. 11 (2012), 527–540.
6. Cardoso, M.M., Peca, I.N., Roque, A.C., Antibody-conjugated nanoparticles for therapeutic applications. Curr. Med. Chem. 19 (2012), 3103–3127.
7. Cerasoli, E., Ravi, J., Garfagnini, T., Gnaniah, S., le Pevelen, D., Tranter, G.E., Temperature denaturation and aggregation of a multi-domain protein (IgG1) investigated with an array of complementary biophysical methods. Anal. Bioanal. Chem. 406 (2014), 6577–6586.
8. Chanphai, P., Bekale, L., Tajmir-Riahi, H.A., Effect of hydrophobicity on protein–protein interactions. Eur. Polym. J. 67 (2015), 224–231.
9. Elvin, J.G., Couston, R.G., van der Walle, C.F., Therapeutic antibodies: market considerations, disease targets and bioprocessing. Int. J. Pharm. 440 (2013), 83–98.
10. Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor. Endocr. Rev. 18 (1997), 4–25.
11. Fonte, P., Soares, S., Sousa, F., Costa, A., Seabra, V., Reis, S., Sarmento, B., Stability study perspective of the effect of freeze-drying using cryoprotectants on the structure of insulin loaded into PLGA nanoparticles. Biomacromolecules 15 (2014), 3753–3765.
12. Hawe, A., Kasper, J.C., Friess, W., Jiskoot, W., Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur. J. Pharm. Sci. 38 (2009), 79–87.
13. Joshi, V., Shivach, T., Yadav, N., Rathore, A.S., Circular dichroism spectroscopy as a tool for monitoring aggregation in monoclonal antibody therapeutics. Anal. Chem. 86 (2014), 11606–11613.
14. Kaja, S., Hilgenberg, J.D., Everett, E., Olitsky, S.E., Gossage, J., Koulen, P., Effects of dilution and prolonged storage with preservative in a polyethylene container on bevacizumab (Avastin™) for topical delivery as a nasal spray in anti-hereditary hemorrhagic telangiectasia and related therapies. Hum. Antibodies 20 (2011), 95–101.
15. Kelly, S.M., Price, N.C., The use of circular dichroism in the investigation of protein structure and function. Curr. Protein Pept. Sci. 1 (2000), 349–384.
16. Kelly, S.M., Jess, T.J., Price, N.C., How to study proteins by circular dichroism. Biochim. Biophys. Acta 1751 (2005), 119–139.
17. Li, F., Hurley, B., Liu, Y., Leonard, B., Griffith, M., Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration. Open Ophthalmol. J. 6 (2012), 54–58.
18. Lin, J.C., Glover, Z.K., Sreedhara, A., Assessing the utility of circular dichroism and FTIR spectroscopy in monoclonal-antibody comparability studies. J. Pharm. Sci. 104 (2015), 4459–4466.
19. Luo, S., Zhang, B., Dextrose-mediated aggregation of therapeutic monoclonal antibodies in human plasma: implication of isoelectric precipitation of complement proteins. MAbs 7 (2015), 1094–1103.
20. Matheus, S., Friess, W., Mahler, H.-C., FTIR and nDSC as analytical tools for high-concentration protein formulations. Pharm. Res. 23 (2006), 1350–1363.
21. Nerlove, M., Wallis, K.F., Use of the Durbin-Watson statistic in inappropriate situations. Econometrica 34 (1966), 235–238.
22. Nicoud, L., Lattuada, M., Yates, A., Morbidelli, M., Impact of aggregate formation on the viscosity of protein solutions. Soft Matter 11 (2015), 5513–5522.
23. Oliva, A., Llabrés, M., Fariña, J.B., Fitting bevacizumab aggregation kinetic data with the Finke–Watzky two-step model: effect of thermal and mechanical stress. Eur. J. Pharm. Sci. 77 (2015), 170–179.
24. Penson, R.T., Huang, H.Q., Wenzel, L.B., Monk, B.J., Stockman, S., Long, H.J. 3rd, Ramondetta, L.M., Landrum, L.M., Oaknin, A., Reid, T.J., Leitao, M.M., Method, M., Michael, H., Tewari, K.S., Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial. Lancet Oncol. 16 (2015), 301–311.
25. Rathore, A.S., Winkle, H., Quality by design for biopharmaceuticals. Nat. Biotechnol. 27 (2009), 26–34.
26. Royer, C.A., Probing protein folding and conformational transitions with fluorescence. Chem. Rev. 106 (2006), 1769–1784.
27. Samuel, D., Kumar, T.K., Ganesh, G., Jayaraman, G., Yang, P.W., Chang, M.M., Trivedi, V.D., Wang, S.L., Hwang, K.C., Chang, D.K., Yu, C., Proline inhibits aggregation during protein refolding. Protein Sci. 9 (2000), 344–352.
28. Sattar, Z., Iranfar, H., Asoodeh, A., Saberi, M.R., Mazhari, M., Chamani, J., Interaction between holo transferrin and HSA-PPIX complex in the presence of lomefloxacin: an evaluation of PPIX aggregation in protein-protein interactions. Spectrochim. Acta A Mol. Biomol. Spectrosc. 97 (2012), 1089–1100.
29. Schellekens, H., The immunogenicity of therapeutic proteins. Discov. Med. 9 (2010), 560–564.
30. Seelig, J., Schonfeld, H.J., Thermal protein unfolding by differential scanning calorimetry and circular dichroism spectroscopy two-state model versus sequential unfolding. Q. Rev. Biophys., 49, 2016, e9.
31. Smith, L.J., Fiebig, K.M., Schwalbe, H., Dobson, C.M., The concept of a random coil: residual structure in peptides and denatured proteins. Fold. Des. 1 (1996), R95–R106.
32. Vermeer, A.W., Norde, W., The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys. J. 78 (2000), 394–404.
33. Weiner, G.J., Building better monoclonal antibody-based therapeutics. Nat. Rev. Cancer 15 (2015), 361–370.
34. Yang, H., Yang, S., Kong, J., Dong, A., Yu, S., Obtaining information about protein secondary structures in aqueous solution using Fourier transform IR spectroscopy. Nat. Protoc. 10 (2015), 382–396.
35. Zhang, H., Huang, Z., Zou, X., Liu, T., Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget, 2016.